Case Report

Posterior reversible encephalopathy syndrome in a patient with HIV/AIDS and immune reconstitution syndrome: a case study and literature review

Zoe F. Weiss1,*, Josiah Rich2 and Edward J. Wing2

1Department of Internal Medicine, Warren Alpert Medical School, Brown University, Providence, RI, USA, and 2Division of Infectious Disease, Warren Alpert Medical School, Brown University, The Miriam Hospital, Providence, RI, USA

*Correspondence address. 593 Eddy St, Providence, RI 02906, USA. Tel: +1-401-595-5889; Fax: +1-401-444-3056; E-mail: zoe.weiss@lifespan.org, zoe_weiss@brown.edu

Abstract

The etiology of posterior reversible encephalopathy (PRES) is typically multifactorial. Patients with HIV are at risk for the development of this syndrome. We review 17 published cases of HIV and PRES and describe the second reported case of PRES in the setting of HIV and immune reconstitution syndrome (IRIS). IRIS has not yet been described as a risk factor for PRES.

INTRODUCTION

Posterior reversible encephalopathy syndrome (PRES) is a neurotoxic syndrome characterized by altered mental status, seizures, headaches, cortical blindness and classic posterior cerebral edema on radiographic imaging. The mechanism of cellular injury is related to breakdown of the blood brain barrier resulting in vasogenic edema. Immunosuppressed patients are at increased risk of PRES [1-3]. HIV infection has been associated with PRES either via endothelial inflammation or immune activation [4]. There are 17 previously reported cases of HIV and PRES and only one other case of PRES and immune reconstitution syndrome (IRIS) has been described in the literature.

CASE PRESENTATION

A 39-year-old man with previously untreated HIV was admitted with 1 year of progressive weight loss, altered mentation and recurrent thrush. On presentation, he was hemodynamically stable with significant cachexia, confusion and mild desaturations with ambulation. His CD4+ count was 9 cells/μl and HIV RNA level >1.5 million copies/ml. Extensive workup for co-infections was initially negative (including cryptococcal antigen, CSF PCR for HSV, EBV and JC virus). Computed tomography (CT) of the chest/abdomen/pelvis revealed diffuse lymphadenopathy and an initial MRI brain was unremarkable. The patient was started on fluconazole, prophylactic azithromycin and trimethoprim/sulfamethoxazole. Once medically stabilized, he initiated HAART therapy (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate), and was discharged with close outpatient monitoring.

The patient returned 10 days later with fever to 103 °F, night sweats, cough, headache, myalgias, diarrhea and abdominal pain. He was found to have axillary lymphadenopathy, tense ascites and renal failure (Cr 1.5 mg/dl, baseline 0.9 mg/dl). Initial blood and sputum cultures were positive for Mycobacterium avium-intracellulare (MAI). Subsequent biopsy of a large right
axillary lymph node also revealed MAI. His acutely worsening condition was felt to be consistent with IRIS in the setting of disseminated MAI and the recent initiation of HAART therapy. He began anti-mycobacterial treatment with clarithromycin and ethambutol and high dose steroids (dexamethasone 4 mg BID) to control his IRIS. Due to renal failure, his HAART therapy was altered to include dolutegravir, abacavir and lamivudine.

Over the next 3 days he was noted to have persistent hypertension up to 180/90 mmHg and worsening renal function with a creatinine to 2.8 mg/dl. He developed severe headaches, confusion, fluctuating visual changes, a new left homonymous hemianopsia, and one witnessed seizure. MRI brain showed multifocal T2/FLAIR hyperintensities favoring the parietal and occipital lobes with evidence of parieto-occipital hemorrhage (Fig. 1). His blood pressure was medically controlled with clonidine and amlodipine. His neurologic symptoms improved over 1 week, at which point steroids were switched to oral prednisone and slowly tapered. Repeat MRI after 8 days from the initial seizure showed marked improvement with some residual hemorrhage and diffusion restriction in the right parieto-occipital region. His neurologic symptoms and reversible MRI findings were consistent with PRES. CNS IRIS and posterior multifocal leukoencephalopathy (PML) were considered on the differential, however, the symmetric and posterior distribution, rapid improvement and negative JC virus made these diagnoses less likely. At 1 year he had near complete resolution of neurologic symptoms with a mild stable left homonymous hemianopsia.

**DISCUSSION**

PRES is a clinic-radiological entity characterized by headache, seizures, focal neurologic deficits and classic neuroimaging findings of bilateral subcortical parieto-occipital vasogenic edema that resolves or improves with management of underlying etiologies [1]. PRES has been described in patients with severe hypertension, renal failure, immunosuppression, organ transplantation, cytotoxic chemotherapies, eclampsia, sepsis, blood transfusions, hypercalcemia and high dose steroids [1, 5–8]. Despite the reportedly high prevalence among patients with autoimmune disorders and immunosuppression, only 17 other cases of HIV and PRES have been reported in the literature, one of which presented with concurrent IRIS. Given the relatively recent discovery of PRES and the clinical and radiographic similarities to PML, PRES is likely more common than currently reported among HIV patients [9].

Like most patients with PRES, our patient had a combination of associated conditions including an acute hypertensive episode, renal failure, immunosuppression, systemic infection and steroid use. Nearly all documented cases of HIV and PRES present with multiple potential risk factors (see Table 1) including hypertension (13/18), renal failure (9/18), systemic or...
opportunistic infection (11/18), recent HAART therapy (3/18), chronic HAART therapy (6/18), steroid administration (3/18) and hypercalcemia (3/18). The 11/18 patients had documented CD4 counts <200 cells/μL. Of those patients with hypertensive episodes (SBP > 140 mmHg), median systolic blood pressure was 192 mmHg. Systemic diseases present included MAI (three cases), tuberculosis (two cases), thrombotic thrombocytopenic purpura (two cases) and varicella zoster virus (two cases). Two cases occurred in patients on long-term successful anti-retroviral therapy with unexplained hypertensive crises and two cases were documented in patients with HIV and no other risk factors.

The underlying pathophysiology of PRES is controversial. Three main mechanisms have been hypothesized including (i) hypertension induced hyperperfusion and vasogenic edema, (ii) cerebrovascular endothelial cytotoxicity, and more recently proposed (iii) immune mediated endothelial damage [4, 7]. The immune mediated pathogenesis suggests that pathological activation of T-cells leads to inflammatory cytokine production, endothelial damage and ultimately disruption of the blood brain barrier [7, 10, 11]. The relationship between HIV and PRES is not fully understood. The HIV virus alone may be a risk factor for PRES, as HIV precipitates cytokine mediated inflammatory pathways resulting in damage to cerebrovascular endothelial cells [4, 12, 13]. Anti-retroviral therapies, specifically protease inhibitors, have also been associated with hypertension and endothelial dysfunction directly or by way of metabolic derangements which may further predispose patients to the development of PRES [14–16].

In addition to one other documented case, our patient also had IRIS, a condition characterized by T-cell activation and paradoxical clinical deterioration after initiation of HAART therapy [17]. Though IRIS has not yet been described as a risk factor or etiology for the development of PRES, it shares the characteristic systemic aberrant T-cell activation seen in other predisposing conditions and supports an autoimmune pathogenesis.

HIV has been associated with PRES, a neurotoxic condition caused by damage to the blood brain barrier. IRIS may be an unrecognized risk factor via massive T-cell activation. Clinicians should consider PRES in patients with HIV and IRIS who develop acute neurologic symptoms. Favorable outcomes are reported with management of underlying etiologies.

CONFLICT OF INTEREST STATEMENT

Authors have no relevant financial or non-financial relationships or conflicts of interest to disclose.

FUNDING

No funding to report.

ETHICAL APPROVAL

None required.

CONSENT

The patient consented to be included in this case report. No PHI is included.

GUARANTOR

Dr Zoe Weiss.

REFERENCES

1. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996; 334:494–500.
2. Legtie S, Schraub O, Azoulay E, et al. Determinants of recovery from severe posterior reversible encephalopathy syndrome. PLoS One 2012;7:e44534.
3. Mirza A. Posterior reversible encephalopathy syndrome: a variant of hypertensive encephalopathy. J Clin Neurosci 2006; 13:590–5.
4. Nightingale S, Wood C, Ainsworth J. The posterior reversible encephalopathy syndrome in HIV infection. Case Rep 2012; 2012:bcr0120125647.
5. Camara-Lemarroy CR, Gonzalez-Moreno EL, Ortiz-Corona Jde J, et al. Posterior reversible encephalopathy syndrome due to malignant hypercalcemia: physiopathological considerations. J Clin Endocrinol Metab 2014:99:1112–6.
6. Kumar S, Rajam L. Posterior reversible encephalopathy syndrome (PRES/RPLS) during pulse steroid therapy in macrophage activation syndrome. Indian J Pediatr 2011;78:1002–4.
7. Granata G, Greco A, Iannello G, et al. Posterior reversible encephalopathy syndrome—insight into pathogenesis, clinical variants and treatment approaches. Autoimmun Rev 2015;14:830–6.
8. Fugate JE, Claassen DO, Cloft HJ, Kallmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc 2010;85:427.
9. Kahn JS, Romano S, Andiman WA. A reversible posterior leukoencephalopathy syndrome [Letter; comment]. N Engl J Med 1996;334:1745.
10. Bartynski WS. Posterior reversible encephalopathy syndrome, Part 2: Controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol 2008;29:1043–9.
11. Horbinski C, Bartynski WS, Carson-Walter E, Hamilton RL, Tan HP, Cheng S. Reversible encephalopathy after cardiac transplantation: histologic evidence of endothelial activation, T-cell specific trafficking, and vascular endothelial growth factor expression. AJNR Am J Neuroradiol 2009;30:588–90.
12. Yang B, Singh S, Bressani R, Kamnoge GD. Cross-talk between STAT1 and PI3K/AKT signaling in HIV-1-induced blood-brain barrier dysfunction: role of CCR5 and implications for viral neuropathogenesis. J Neurosci Res 2010;88:3090–3101.
13. Hawkins BT. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev 2005;57:173–85.
14. Ridolfo AL, Resta F, Milazzo L, et al. Reversible posterior leukoencephalopathy syndrome in 2 HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis 2008;46:e19–22.
15. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001;104:257–62.
16. Giner V, Fernández C, Esteban MJ, et al. Reversible posterior leukoencephalopathy secondary to indinavir-induced hypertensive crisis: a case report. Am J Hypertens 2002;15:465–7.
17. Bonham S, Meya DB, Bobjanen PR, Boulware DR. Biomarkers of HIV immune reconstitution inflammatory syndrome. Biomark Med 2008;2:349–61.
18. Chang OH-C, Stanculescu A, Dola C, Rothwell WB. Recurrent posterior reversible encephalopathy syndrome
potentially related to AIDS and end-stage renal disease: a case report and review of the literature. Case Rep Med 2012;2012:914035.

19. Kurukumbi M, Castellanos MI, Crawford AK, Gowdar SD, Jayam-Trouth A. Posterior reversible encephalopathy syndrome in a patient with newly diagnosed HIV infection and end stage renal disease. Case Rep Neurol Med 2013;2013:1–5.

20. Saeed MU, Dacucuy MAC, Kennedy DJ. Posterior reversible encephalopathy syndrome in HIV patients: case report and review of the literature. AIDS 2007;21:781–2.

21. Frank Y, Pavlakis S, Black K, Bakshi S. Reversible occipital-parietal encephalopathy syndrome in an HIV-infected child. Neurology 1998;51:915–6.

22. Sylvester SL, Diaz LA Jr, Port JD, Sterling TR. Reversible posterior leukoencephalopathy in an HIV-infected patient with thrombotic thrombocytopenic purpura. Scand J Infect Dis 2002;34:706–9.

23. Sasson SC, Oon A, Chagantri J, Brew BJ, Carr A. Posterior reversible encephalopathy syndrome (PRES) in an HIV-1 infected patient with disseminated varicella zoster virus: a case report. BMC Infect Dis 2013;13:396. http://dx.doi.org/10.1186/1471-2334-13-396.

24. Stevenson J, Taylor C. Posterior reversible encephalopathy syndrome in disseminated histoplasmosis and advanced HIV infection. Int J STD AIDS 2014;25:611–3.

25. Kupper MF, Rieg S, Venhoff N, et al. GMS. Kongress für Infektionskrankheiten und Tropenmedizin (KIT 2010. Posterior reversible encephalopathy syndrome (PRES) and HIV/tuberculosis co-infection. Available at: https://www.egms.de/static/en/meetings/kit2010/10kit194.shtml (28 June 2018, date last accessed).

26. Guerriero S, Ciraci L, et al. Bilateral visual loss as presenting symptom of posterior reversible encephalopathy syndrome in a patient with HIV/Tuberculosis coinfection: a case report. Case Rep Ophthalmol Med 2012;2012:1–4.

27. Wilbanks L, Hayat G. A case of posterior reversible encephalopathy syndrome associated with HIV (P04.008). Neurology 2013;80:P04.008.

28. Choudhary M, Rose F. Posterior reversible encephalopathic syndrome due to severe hypercalcemia in AIDS. Scand J Infect Dis 2005;37:524–6.

29. Viehman JA, Khalil D, Barhoma C, Hanna RM. Mycobacterium avium-intracellulare otomastoiditis in a young AIDS patient: case report and review of the literature. HIV AIDS (Auckl) 2013;5:61–6. doi:10.2147/HIV.S36545.